Home/Pipeline/QL325

QL325

Acute Myeloid Leukemia

Phase 1Active

Key Facts

Indication

Acute Myeloid Leukemia

Phase

Phase 1

Status

Active

Company

QLSF Biotherapeutics

About QLSF Biotherapeutics

QLSF Biotherapeutics is a private, clinical-stage biotech founded in 2020 and headquartered in South San Francisco, California. The company has built a robust pipeline of novel bispecific antibodies and cytokine fusion proteins targeting multiple immune-oncology mechanisms, with several programs already in Phase 1/2 clinical trials. Its strategy is driven by tumor biology, categorizing approaches for 'Myeloid Rich,' 'Immunologically Cold,' and 'Inflamed' tumor microenvironments. QLSF benefits from strong financial and clinical development support from a strategic partner, Qilu Pharmaceutical, which is advancing key assets in clinical studies.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia Drugs

Drug	Company	Phase	Status
AFM28	Affimed	Phase 1/2	Active
AML (N-Act) AI	Biostate AI	Development	Active
Navtemadlin (KRT-232)	Kartos Therapeutics	Phase 1/Phase 2	Active
NPM1 Testing in AML	Diatech Pharmacogenetics	Commercial	Active
Joint Development for AML	Ordaos Bio	Pre-clinical	Active
DFP Oncology Program	Delta-Fly Pharma	Preclinical	Active
TRIB1 degrader	FIMECS	Discovery	Active
NG-202	Nanogen Pharmaceutical Biotechnology	Preclinical	Active
LBS-007	Lin BioScience	Phase 1/2	Active
RG6356 (RO7434656)	Chugai Pharmaceutical	Phase III	Active
AL8326	Shanghai Allist Pharmaceuticals	Phase II	Active
GT1709	Kintor Pharma	Phase 1	Active